Core Viewpoint - Spring Medical experienced a slight decline in stock price on December 31, with a trading volume of 24.47 million yuan, indicating a potential shift in investor sentiment and market dynamics [1] Financing Summary - On December 31, Spring Medical had a financing buy-in amount of 1.23 million yuan and a financing repayment of 1.39 million yuan, resulting in a net financing outflow of 0.15 million yuan [1] - The total financing and securities lending balance for Spring Medical reached 38.24 million yuan, with the financing balance accounting for 0.58% of the circulating market value, which is above the 70th percentile level over the past year, indicating a relatively high position [1] - The securities lending aspect showed no shares were repaid or sold on December 31, with a remaining securities lending volume of 200 shares and a balance of 4,576 yuan, also exceeding the 80th percentile level over the past year [1] Company Overview - Beijing Spring Medical Equipment Co., Ltd. was established on February 12, 1998, and went public on December 30, 2021, focusing on the research, production, and sales of implantable orthopedic medical devices [2] - The company's main products include joint prosthetics and spinal implant products, covering major human joints such as hip, knee, shoulder, and elbow, with a comprehensive range of spinal fixation systems [2] - As of September 30, Spring Medical reported a revenue of 756 million yuan for the first nine months of 2025, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% [2] Dividend and Shareholder Information - Since its A-share listing, Spring Medical has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2][3] - Notable institutional shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 2.96 million shares, and new entrants like China Europe Economic Growth Mixed A Fund and Ping An Low Carbon Economy Mixed A Fund [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688013 证券简称：天臣医疗 公告编号：2026-001 天臣国际医疗科技股份有限公司 关于自愿披露签订战略合作协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 履约的重大风险及不确定性：本次签订的战略合作协议不涉及金额，具体合作内容以双方另行签订的 合同为准。本协议为双方基于未来合作意向签署的框架性、原则性协议，不构成对具体合作项目、实施 进度或商业成果的实质性承诺。协议履行过程中，若受行业政策调整、市场环境变化等不可预见因素或 不可抗力影响，可能导致协议无法如期履行或履行效果未达预期。公司将根据协议履行情况及后续合作 进展，按照《上海证券交易所科创板股票上市规则》等相关法律法规、规范性文件的规定，及时履行信 息披露义务，敬请投资者注意投资风险。 ● 对公司业绩的影响：本协议属于框架性协议，预计对天臣国际医疗科技股份有限公司（以下简称"公 司"或"天臣医疗"）2026年度及未来业绩不构成直接影响，对公司业绩的具体影响需视下一步具 ...

Group 1 - The A-share medical device sector experienced a significant increase, with the industry index rising by 5.64% on January 5, 2025, and over 60 billion yuan of net inflow from major funds into the sector [1] - The National Medical Products Administration (NMPA) announced adjustments to the management categories of 31 types of medical devices, introducing new categories and refining existing classifications to better align with technological advancements and regulatory needs [1] - The adjustments include the addition of innovative medical devices such as biodegradable magnesium metal clips and tendon repair patches, while also simplifying regulations for low-risk products like manual wheelchairs [1] Group 2 - Recent favorable policies have emerged for the medical device industry, including the NMPA's initiatives to optimize lifecycle regulation and prioritize the approval of high-end medical devices, which aim to accelerate the registration process and market entry [2] - The medical device industry is experiencing growth driven by policy support and market demand, leading to trends such as industry consolidation, increased market concentration, and ongoing investment in research and development [2] - China's medical device export volume continues to grow, with a total export value of 24.1 billion USD in the first half of 2025, reflecting a 5% increase compared to the same period in 2024 [2] Group 3 - Century Securities noted that domestic medical device manufacturers have gained significant market share following extensive centralized procurement, which is expected to benefit from scale effects and export policies [3] - Among the 133 listed companies in the A-share medical device sector, over 70% of those disclosing overseas revenue reported year-on-year growth, with six companies exceeding 1 billion yuan in overseas revenue in the first half of 2025 [3] - Mindray Medical's overseas revenue has consistently increased from 2.615 billion yuan in 2014 to 16.434 billion yuan in 2024, with international revenue expected to account for approximately 50% of total revenue in the first half of 2025 [3] Group 4 - Medical device companies are increasingly focusing on research and development, with 67 companies reporting R&D expenses exceeding 20% of their operating income, indicating a strong commitment to innovation within the sector [4] - Companies like Zhijiang Biology are making significant advancements in core technologies, including nanomagnetic beads and membrane materials, contributing to progress in cutting-edge areas such as membrane technology and organ-on-a-chip systems [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603014 证券简称：威高血净 上市地：上海证券交易所 山东威高血液净化制品股份有限公司 发行股份购买资产暨关联交易报告书（草案）摘要 ■ 独立财务顾问 一、上市公司声明 本重大资产重组报告书摘要的目的仅为向公众提供有关本次重组的简要情况，并不包括重大资产重组报 告书全文的各部分内容。重大资产重组报告书全文同时刊载于上海证券交易所网站 （www.sse.com.cn）。 ■ 签署日期：二零二六年一月 声 明 本部分所述词语或简称与本报告书摘要"释义"所述词语或简称具有相同含义。 本公司及本公司全体董事、高级管理人员承诺本报告书摘要及相关信息真实、准确、完整，不存在虚假 记载、误导性陈述或者重大遗漏，并对所提供信息的真实性、准确性、完整性承担相应的法律责任。 如本次交易所披露或提供的信息涉嫌虚假记载、误导性陈述或者重大遗漏，被司法机关立案侦查或者被 中国证监会立案调查的，在形成调查结论以前，不转让在上市公司拥有权益的股份，并于收到立案稽查 通知的两个交易日内将暂停转让的书面申请和股票账户提交上市公司董事会，由上市公司董事会代为向 证券交易所和证券登记 ...

在人工智能发展浪潮下，从加速新药研发进程，到赋能临床精准诊疗，再到驱动医疗产业创新升级，医 工融合正从"单点突破"迈向"全域开花"，为守护人民群众生命健康提供更有力的科技支撑。 更快！有望缩短新药研发周期 新药研发，如同在巨大迷宫中找到一条正确的路径，周期往往极为漫长。能否提升试错效率？AI被寄 予厚望。 日前，我国自主研发的开放式、普惠性AI制药平台——"AI孔明"正式发布。其在疟疾、结核病以及病毒 等全球健康挑战的相关数据库，向全球免费开放。 "该平台已经在数十条真实研发管线中完成系统验证，相较传统流程，候选分子命中率与优化效率实现 了数倍至数十倍的显著提升。"全球健康药物研发中心首席运营官陆漫春说。 研发团队领队、全球健康药物研发中心数据科学部负责人郭晋疆介绍，在"AI孔明"制药平台中，开发了 AI分子设计模型、高精度虚拟筛选、多任务ADMET评估模型等原创算法，覆盖"靶点结构分析、AI分 子生成与优化、活性筛选、成药性评估"全流程，压缩传统药物研发时间。 当AI与医学、工程技术相遇，将会碰撞出哪些火花？ 目前，这项成果已在北京协和医院等地进行临床试验。在AI音律引导下，原本步态僵硬、不协调的患 者，步 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 广州维力医疗器械股份有限公司（以下简称"公司"）全资子公司江西狼和医疗器械有限公司（以下简 称"狼和医疗"）于近日收到由江西省科学技术厅、江西省财政厅、国家税务总局江西省税务局联合颁发 的《高新技术企业证书》，具体情况如下： 证券代码：603309 证券简称：维力医疗 公告编号：2026-002 证书编号：GR202536000490 发证日期：2025年10月29日 有效期：三年 狼和医疗于2013年被认定为高新技术企业，并分别于2016年、2019年、2022年通过了复审认定，本次高 新技术企业认定是原证书有效期满后进行的重新认定。 根据《中华人民共和国企业所得税法》等有关规定，狼和医疗自获得高新技术企业认定当年起三年内 （即2025年、2026年、2027年），将继续享受国家关于高新技术企业的相关优惠政策，即按15%的税率 计缴企业所得税。 广州维力医疗器械股份有限公司 关于全资子公司通过高新技术企业 重新认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 本公司 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 ■ 上述医疗器械注册证的取得，有利于丰富公司的产品种类，满足市场需求，增强公司的核心竞争能力。 但上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后的实销售情况取决于未来 市场的推广效果，公司目前尚无法预测上述产品对公司未来营业收入的具体影响。敬请投资者理性投 资，注意投资风险。 爱威科技股份有限公司（以下简称"爱威科技"、"公司"）及其子公司湖南爱威医疗科技有限公司（以下 简称"湖南爱威"）自2025年10月1日起至2025年12月31日 取得境内专利证书11项，其中发明专利5项、 实用新型专利1项、外观设计专利5项；取得境外专利1项；取得医疗器械注册证1项。具体情况如下： 一、专利证书 （1）境内专利 ■ （2）境外专利 ■ 上述专利的取得是公司重要核心技术的体现和延伸，有利于进一步完善公司知识产权保护体系， 发挥 自主知识产权的技术优势，促进技术创新，从而提升公司核心竞争力。 二、医疗器械注册证 特此公告。 爱威科技股份有限公司董事会 2026年1月1日 ...

Core Viewpoint - The A-share market experienced a strong opening on January 5, 2026, with all three major indices rising significantly, indicating a bullish sentiment among investors and a potential continuation of the upward trend in 2026 [1][3]. Market Performance - The Shanghai Composite Index closed up 1.38% at 4023.42 points, marking a 12-day consecutive rise, the longest in over 30 years [3]. - The Shenzhen Component Index and the ChiNext Index rose by 2.24% and 2.85%, closing at 13828.63 points and 3294.55 points, respectively [3]. - The STAR 50 Index saw a notable increase of 4.4%, closing at 1403.41 points [3]. Trading Activity - The total trading volume on January 5 reached approximately 2.55 trillion yuan, with the Shanghai Stock Exchange contributing 1.067 trillion yuan and the Shenzhen Stock Exchange 1.479 trillion yuan [3][4]. - A total of 4185 stocks rose, with 127 stocks hitting the daily limit up, indicating a strong profit-taking environment for investors [4]. Sector Performance - The brain engineering sector led the gains, with several stocks hitting the daily limit up, including Sanbo Brain Science and Botao Biology [3]. - Other active sectors included insurance, fourth-generation semiconductors, medical devices, and AI pharmaceuticals, all showing significant upward movement [3]. Future Outlook - Analysts predict a continued inflow of capital into the A-share market, potentially reaching 1.56 trillion yuan, which would support a slow bull market [4]. - The core logic supporting the current bull market remains unchanged, driven by ongoing policy support, a significant shift in household savings, and advancements in technological innovation [4]. - The current market is characterized as a slow bull market, which could last from 3 to 10 years, marking a golden investment period for the Chinese capital market [4].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Hangzhou Diagens Biotechnology Co., Ltd. 杭州德適生物科技股份有限公司 (the "Company") (A joint stock company incorporated in the ...

Core Viewpoint - The A-share market experienced a strong opening on January 5, 2026, with all three major indices rising significantly, marking a notable bullish trend and a potential continuation of the "slow bull" market phase for the coming years [1][3][5]. Market Performance - On January 5, the Shanghai Composite Index rose by 1.38% to close at 4023.42 points, achieving a "12 consecutive days of gains" record, the longest in over 30 years [3]. - The Shenzhen Component Index and the ChiNext Index increased by 2.24% and 2.85%, closing at 13828.63 points and 3294.55 points, respectively [3]. - The STAR 50 Index saw a remarkable increase of 4.4%, closing at 1403.41 points [3]. Trading Activity - The trading atmosphere was robust, with a total trading volume of approximately 2.55 trillion yuan across both the Shanghai and Shenzhen markets [1][3]. - The Shanghai Stock Exchange recorded a trading volume of 1.0673 trillion yuan, while the Shenzhen Stock Exchange had 1.4790 trillion yuan [3]. Sector Performance - The human brain engineering sector led the gains, with several stocks hitting the daily limit up, including Sanbo Brain Science and Botao Biology [3]. - Other active sectors included insurance, fourth-generation semiconductors, medical devices, and AI pharmaceuticals, all showing significant upward movement [3]. Individual Stock Highlights - China Satellite topped the individual stock trading volume with 19.454 billion yuan, followed closely by Sanhua Intelligent Control at 19.212 billion yuan [4]. - A total of 4185 stocks rose, with 127 hitting the daily limit up, indicating a strong profit-making effect for investors [4]. Future Outlook - According to a report from招商证券, A-share market is expected to see a net inflow of approximately 1.56 trillion yuan, providing liquidity support for a "slow bull" market [4]. - The core logic supporting the current bull market remains unchanged, driven by continuous policy support, a significant shift in household savings, and advancements in technological innovation [4]. - The current market phase is characterized as a "slow bull" or "long bull" market, potentially lasting 3-10 years, marking a significant investment period for Chinese assets [5].